June 26, 2023
5th Exosome Based Therapeutic Development Summit, September 5-7 at the Hilton Boston Logan Airport
Great presentation by our Head of RA/QA, Dr. Ina Sarel at the Annual Conference for Regulation in Drug development and Production👏🏻 Ina shared valuable and cutting edge on regulatory challenges in scaling up production of Extracellular Vesicles. Read More >>>
Happy to share recent scientific and business developments through EXITEAM CAPITAL PARTNERS! Read More >>>
Great professional analysis report has been published! We invite you to take a deeper look into it in order to see the actual value and pricing of our company! For further information or inquiries, please contact us. Read More >>>
In connection with the collaboration with Particle Metrix, a highly-advanced Nanoparticle Tracking Analysis instrument (“NTA”) – “Zeta view TWIN laser system” has been recently placed at NurExone Biologic’s laboratory, which is an important milestone in the expansion of NurExone’s production and analytic processes. The newly acquired NTA, which is the first
TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company”) (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive imaging results from an internal preclinical study of its investigational drug ExoPTEN. The image analysis and measurements confirmed successful nerve regeneration following
MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the “Company” or “NurExone”) (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle